Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results

Fernando M. Stengel,* Valeria Petri,† Gladys A.M. Campbell,‡ Gladys Leon Dorantes,§ Magdalina Lópe,† Ricardo L. Galimberti,** Raúl P. Valdez,†† Lucia F. de Arruda,‡‡ Mario Amaya Guerra,§§ Edgardo N. Chouela,¶¶ and Daiana Licu,*** on behalf of the International IMP25161 Study Group

*Centro de Educacion Medica e Investigaciones (CEMIC), Clinicas “Norberto Quirno”, Buenos Aires, Argentina; †UNIFESP, Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Sao Paulo, Brazil; ‡Hospital Universitario de Brasilia, Brasilia, Brazil; 3Hospital General de Mexico, Mexico City, Mexico; 4Hospital La Raza, Mexico City, Mexico; **Hospital Italiano de Buenos Aires, Buenos Aires City, Argentina; 6Hospital Universitario Austral, Pilar, Buenos Aires, Argentina; 7Pontificia Universidade Catolica de Campinas, Campinas, Jundiai, Brazil; 8Unidad Medica de Alta Especialidad N°25, IMSS, Monterrey, NL, Mexico; 9Hospital General de Agudos “Dr Cosme Argerich”, Buenos Aires, Argentina; 10Merck Serono SA, Geneva, Switzerland

DOI: 10.1111/j.1753-5174.2009.00024.x

ABSTRACT

Introduction. Psoriasis is a debilitating, chronic inflammatory systemic disease affecting around 2% of the South American population. Biological therapies offer the possibility of long-term therapy with improved safety and efficacy.

Methods. We conducted a multicentre, open-label, single-arm, Phase IIIb/IV study of adult patients (18–75 years) with moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy. Patients received efalizumab subcutaneously (1.0 mg/kg/wk). The primary endpoint was the proportion of patients achieving a Physician Global Assessment (PGA) rating of “excellent” or “cleared” at Week 24. Safety outcomes were adverse events (AEs), serious AEs (SAEs) and abnormalities on laboratory tests.

Results. Of 189 patients included in the intent-to-treat and safety populations, 104 (55.0%) were of Hispanic or Latino ethnicity. At Week 24, 92/189 (48.7%) patients achieved or maintained a PGA rating of “excellent” or “cleared”. AEs were reported by 161/189 (85.2%) patients, SAEs by 21/189 (11.1%). One patient died during the study (meningoencephalitis). Laboratory findings were consistent with previous experience.

Conclusions. Efalizumab demonstrated sustained control of psoriasis up to 24 weeks in patients from Latin America, confirming results seen in Phase III studies conducted in North America and Europe.

Key Words. Psoriasis; Efalizumab; Open-label; Phase IIIb/IV; Clinical Trial

Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://www3.interscience.wiley.com/authorresources/onlineopen.html

Introduction

Psoriasis is a T-cell-mediated, chronic inflammatory systemic disorder requiring long-term treatment. Conventional systemic therapies are associated with serious toxicities that can limit long-term use [1]. Efalizumab is a recombinant, humanized, monoclonal immunoglobulin G1 antibody that exerts antipsoriasis effects by blocking T-cell-dependent functions mediated by leucocyte function-associated antigen-1 [2]. Its efficacy and safety have been investigated in a clinical...
development programme based in Europe and North America that included over 2800 patients with moderate-to-severe psoriasis [3–10]. The open-label, Phase IIIb/IV study discussed here was performed to collect confirmatory data on the efficacy and safety of efalizumab in a previously unreported Latin American population.

Methods
This was a 24-week, open-label, single-arm Phase IIIb/IV study (protocol IMP25161; ClinicalTrials.gov registration NCT00287118) conducted in 23 centres in Argentina, Brazil and Mexico between October 2004 and May 2006. Patients aged 18–75 years with moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy were eligible. The extent of psoriasis had to involve at least 10% of total body surface area. Discontinuation of any systemic psoriasis treatment was required prior to commencement of the trial; in the case of biologicals, a 3-month washout period was required. For commencement of the trial; in the case of biologicals, a 3-month washout period was required. For commence of the trial, the subject’s safety following exposure to study drug.

Participants underwent initial screening 14 days prior to the first efalizumab injection. Discontinuation of any systemic psoriasis treatment was mandatory before starting study medication; no washout was required. All participants received efalizumab administered subcutaneously, starting with an initial conditioning dose of 0.7 mg/kg at baseline (study Day 0), followed by 23 weekly doses of 1.0 mg/kg.

Participants were evaluated on study Day 0 and at Weeks 2, 4, 8, 12 and 24 (or at early treatment termination), with a follow-up visit at Week 32. Clinical efficacy assessments performed at all visits included the dynamic Physician Global Assessment (PGA) and the PASI. Quality of life (QoL) was assessed at all visits using the Medical Outcomes Study Short-Form (36-Item) Health Survey (SF-36) and the Dermatology Life Quality Index (DLQI).

The PGA measured the global response of all psoriatic lesions to therapy by comparing the subject’s present condition to baseline photographs or body diagrams. The assessor classified response by considering erythema, scaling, plaque thickness and percentage of body surface area affected. Ratings of cleared and excellent represented a 100% improvement (remission) and 75% to 99% improvement of all clinical signs and symptoms relative to baseline, respectively. The PASI determines the extent of cutaneous psoriasis by dividing the body into 4 anatomical regions (i.e. head, trunk, upper limbs, and lower limbs) and, for each region, grading the severity of erythema, induration/thickness and scaling from 0 for “none” to 4 for “very severe”. The percentage of the region affected by disease (graded from 0 for “none” to 6 for 90% to 100% involvement, is also
determined. A numerical score is derived that evaluates the severity of symptoms in terms of the total body surface area affected: this score can range from 0 to 72, with higher scores indicating more severe disease. The DLQI consists of 10 questions concerning the impact of skin disease and its treatment on a subject’s life over the past week. These questions relate to physical discomfort, emotional distress, work and leisure activities, family and social relationships, sexuality and treatment burden. Each question is posed such that possible responses are “very much”, “a lot”, “a little” or “not at all”; patients can also indicate that particular questions are not relevant. DLQI scores range from 0 to 30, with higher scores indicating greater impact of disease (i.e. poorer QoL).

Safety assessments, which included treatment-emergent AEs, serious AEs (SAEs) and AEs leading to permanent treatment discontinuation, were coded for analysis using MedDRA. Summaries of AEs were prepared by MedDRA System Organ Class and Preferred Term for all events, the most frequent events, all events by severity, all events by relation to trial medication, all SAEs and all AEs leading to withdrawal from treatment. The severity of adverse events was assessed as mild (the patient was aware of the event or symptom but it was easily tolerated), moderate (the patient experienced sufficient discomfort to interfere with, or reduce, his or her usual level of activity), severe (the patient experienced a significant impairment of functioning and was unable to carry out his or her usual activities) or very severe (the patient’s life was at risk from the event). A serious adverse event was defined as an event resulting in death or that was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was a medically important condition (the event did not have to be immediately life-threatening or result in death or hospitalization, but was clearly of major clinical significance). Routine clinical laboratory evaluations comprised haematology (i.e. red blood cell count, haemoglobin, haematocrit, platelet count, white blood cell count and white blood cell differential) and biochemistry tests (i.e. urea and electrolytes, liver function, blood urea nitrogen, blood glucose, creatine phosphokinase, and uric acid) performed at baseline and at Weeks 2, 12 and 24 (or at early treatment termination). Platelet counts were also performed at Weeks 4 and 8.

Analysis Populations
The following populations were defined for analysis:
(a) Intent-to-treat (ITT) and safety population: patients who received ≥1 dose of trial medication.
(b) Per-protocol (PP): all patients who did not have major protocol violations. The PP population was used for supportive analyses of the primary and secondary endpoints.

Outcome Measures
The primary efficacy endpoint was the proportion of patients with a PGA score of “excellent” or “cleared” at Week 24 (ITT and PP populations). The secondary endpoint was the proportion of patients achieving “at least good disease control” at Week 24, defined as a PASI score of <8 or a 50% reduction from baseline in PASI score (PASI-50), a DLQI score of <6, and no SAEs, treatment-related SAEs, or early withdrawal (ITT and PP populations). This endpoint provides a comprehensive assessment of benefit–risk ratio and takes into account the multidimensional aspects of psoriasis. It is similar to the “safe psoriasis control” measure proposed in recent publications [11,12]. The disease control endpoint was also evaluated in a sensitivity analysis, which excluded the PASI-50 measure from the composite endpoint (i.e. the only PASI requirement was a score of <8).

Tertiary endpoints were the proportion of patients achieving a ≥75% reduction from baseline in PASI score (PASI-75) and PASI-50; changes in DLQI and SF-36 scores; and changes in scores for the PASI, Nail Psoriasis Severity Index, Palmoplantar Pustular Psoriasis Area and Severity Index, and Psoriasis Scalp Severity Index (ITT population). Results of the nail, scalp and palmoplantar psoriasis assessments are reported elsewhere [13].

Analyses of efficacy in the ITT population were performed using the last observation carried forward (LOCF) approach. The primary endpoint was also analysed using the nonresponder imputation technique, in which all patients with missing data at Week 24 were counted as nonresponders. No formal hypothesis testing or adjustments were performed. It was estimated that 220 patients would have to be screened to yield a sample of sufficient size to accurately assess efalizumab’s safety and efficacy profile in this target population.
Results

Between October 2004 and September 2005, 220 patients were screened, of whom 31 patients were considered screening failures, mostly for reasons related to laboratory results. Thus, 189 were enrolled and received treatment (ITT and safety populations). A total of 137 patients (72.5%) completed the 24-week treatment period. The main reasons for discontinuation from the treatment period were AEs in 30 patients (57.7%), lack of efficacy in 11 patients (21.2%), and protocol violation by 2 patients (3.8%). The PP population comprised 124 patients.

The median age of patients in the ITT population was 46 years (range 19–74 years), two-thirds were men, and 55% were of Hispanic or Latino ethnicity (Table 1). The mean ± standard deviation (SD) PASI score at baseline was 24 ± 9.5 and 59.0% had a baseline PASI score of ≥20 points. Reported medications at baseline were typical of a psoriasis population, with nonsteroidal anti-inflammatory drugs, analgesics and topical psoriasis medications frequently used. The mean (±SD) time on treatment was 139 ± 45 days. Almost two-thirds of patients (64.5% [122/189]) received all 24 planned weekly injections.

Endpoints

In the ITT population, 48.7% (92/189) of patients achieved or maintained a PGA score of “excellent” or “cleared” (95% confidence interval [CI] 41.6–55.8%; Fig. 1a) at Week 24 (nonresponder imputation analysis 46.0% [87/189]; 95% CI 38.9–53.1%); in the PP population this rate was 65.3% (81/124; 95% CI 56.9–73.7%). At Week 24, 67.7% (128/189) in the ITT population achieved or maintained a PGA score of “good” or better (Fig. 1a).

In the ITT population, 47.1% (89/189) achieved “at least good disease control” at Week 24 (95% CI 40.0–54.2%); in the PP population this rate was 65.3% (81/124; 95% CI 56.9–73.7%). “Safe disease control” at Week 24 was achieved by 50.0% (62/124; 95% CI 41.2–58.8%) in the PP population and 36.0% (68/189; 95% CI 29.1–42.8%) in the sensitivity analysis.

At Week 24, 90 patients (47.6%; 95% CI 40.5–54.7%) were classified as PASI-75 responders and 132 (69.8%; 95% CI 63.3–76.4%) were classified as PASI-50 responders (Fig. 1b).

Median PASI and DLQI scores with respect to study visit are summarized in Table 2. Percentage change from baseline in PASI score improved by visit (Fig. 1c). At Week 12, the median percentage change from baseline was 61.9% (interquartile range 34–79%) and the mean ± SD was 49.0% ± 44.0%; at Week 24, using LOCF, the median percentage change from baseline had increased to 72.8% (95% CI 65.3–78.6%) and the mean ± SD had increased to 55.2% ± 44.0%.

Safety and Tolerability

During the treatment phase, 161/189 (85.2%) patients reported at least one AE; 152 (80.4%) experienced at least one AE during Weeks 0–12 vs

---

**Table 1** Baseline demographic and disease characteristics of the intent-to-treat population (N = 189)

| Characteristic | Value |
|---------------|-------|
| Median age (range), years | 46 (19–74) |
| Male, n (%) | 134 (70.9) |
| Race, n (%) | | |
| White | 125 (66.1) |
| Black | 7 (3.7) |
| Asian | 0 |
| Other | 57 (30.2) |
| Hispanic or Latino ethnicity, n (%) | 104 (55.0) |
| Median weight (range), kg | 80 (46–120) |
| Median body mass index (range), kg/m² | 28.7 (16.5–45.3) |
| Median duration of psoriasis (range), years* | 15 (1–46) |
| Patients with prior psoriasis therapy, n (%) | 158 (83.6) |
| Patients with prior systemic therapy, n (%)* | 153 (81.0) |
| Median PASI score (range)† | 22 (7–41) |
| PASI score ≥20, n (%)‡ | 111 (59.0) |
| Median DLQI score (range)§ | 11.5 (0–29) |
| Median SF-36 score (range) | | |
| Total score | 550.3 (66.4–778.5) |
| Mental component score | 262.5 (28.0–596.0) |
| Physical component score** | 294.4 (21.7–395.0) |

*Psoralen ultraviolet A therapy, ciclosporin, systemic corticosteroids, methotrexate, systemic retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, azathioprine and 6-mercaptopurine; †N = 180; **N = 177; ‡N = 179.

DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; SF-36, Medical Outcomes Study Short-Form (36-Item) Health Survey.
67 (35.4%) during Weeks 13–24. In 125 patients (66.1%), at least one AE was considered possibly or probably related to efalizumab. The most frequently reported treatment-emergent AEs, particularly during the first 12 weeks, were consistent with the syndrome of “acute AEs” (influenza-like symptoms such as headache, fever, chills, myalgia, nausea or vomiting within 48 hours of administration) (Table 3).

Post-treatment AEs were reported in 69 patients (36.5%), 20 of whom continued with efalizumab after completing the study treatment period. Thirty-one patients (16.4%) experienced a total of 46 treatment-emergent AEs that led to withdrawal of efalizumab; psoriasis (6.3%) and arthritis (2.1%) were the most common AEs cited.

SAEs were reported in 21 patients (11.1%) and included psoriasis, arthritis, arthralgia and

Figure 1 (a) Physician Global Assessment score over time during treatment with efalizumab (intent-to-treat population, last observation carried forward; N = 189). (b) Proportion of responders (95% CI) achieving a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI) score (PASI-75) and a ≥50% reduction from baseline in PASI score (PASI-50) over time during treatment with efalizumab (intent-to-treat population, last observation carried forward). (c) Mean and median (95% CI) percentage improvement in PASI score over time during treatment with efalizumab (intent-to-treat population, last observation carried forward).
myalgia. Post-treatment SAEs were reported in 22 patients (11.6%). Treatment-emergent musculoskeletal and connective tissue disorders (most commonly arthralgia, myalgia, back pain, and arthritis) were reported in 71 patients (37.6%). One patient died during the study from meningoencephalitis probably of bacterial origin. Due to the mechanism of action of efalizumab, it could not be excluded that efalizumab played a role in the evolution of the infection. Five infection-related SAEs occurred in four patients during the treatment period of the study (cytomegalovirus infection, meningitis aseptic, pneumonia, tooth abscess and sepsis [the tooth abscess and sepsis were reported in the subject who died]). The pneumonia, tooth abscess and sepsis were considered to be probably related to the trial medication and the cytomegalovirus infection and

### Table 3
Summary of the most frequent treatment-emergent adverse events (TEAEs) (reported in ≥5% of patients) in the safety population (N = 189)

| Adverse events                  | Number of patients (%) |
|---------------------------------|------------------------|
|                                | Weeks 1–12 | Weeks 13–24 |
| Total                           | 152 (80.4) | 67 (35.4)   |
| Serious TEAEs                   | 15 (7.9)   | 8 (4.2)     |
| Severe or very severe TEAEs     | 29 (15.3)  | 16 (8.5)    |
| Discontinued because of a TEAE  | 21 (11.1)  | 11 (5.8)    |
| TEAE term                       |            |             |
| Headache                        | 68 (36.0)  | 6 (3.2)     |
| Arthralgia                      | 23 (12.2)  | 6 (3.2)     |
| Myalgia                         | 21 (11.1)  | 7 (3.7)     |
| Influenza-like illness          | 20 (10.6)  | 3 (1.6)     |
| Pyrexia                         | 20 (10.6)  | 3 (1.6)     |
| Chills                          | 18 (9.5)   | 0           |
| Back pain                       | 13 (6.9)   | 5 (2.6)     |
| Diarrhoea                       | 13 (6.9)   | 1 (0.5)     |
| Nausea                          | 13 (6.9)   | 1 (0.5)     |
| Influenza                       | 12 (6.3)   | 2 (1.1)     |
| Psoriasis                       | 10 (5.3)   | 8 (4.2)     |

### Table 4
Median (range) clinical laboratory values in the safety population

| Parameter (unit)                  | Visit            | No. pts | Value              | No. pts | Value              | No. pts | Value              |
|-----------------------------------|------------------|---------|--------------------|---------|--------------------|---------|--------------------|
| Red blood cell count (×10¹²/L)    | Baseline         | 186     | 5.0 (3.8–6.9)      | Week 12 | 180     | 5.0 (3.4–6.9)      | Week 24 | 155     | 5.0 (3.6–6.1)     |
| Haemoglobin (g/L)                 | Baseline         | 186     | 151 (114–202)      | Week 12 | 180     | 150 (103–190)      | Week 24 | 155     | 150 (99–189)     |
| Haematocrit                       | Baseline         | 186     | 0.45 (0.36–0.61)   | Week 12 | 180     | 0.45 (0.32–0.62)   | Week 24 | 154     | 0.44 (0.35–0.55) |
| White blood cell count (×10⁹/L)   | Baseline         | 186     | 7.0 (3.8–14.5)     | Week 12 | 180     | 10.0 (5.8–24.7)    | Week 24 | 154     | 10.2 (4.5–17.6)  |
| Lymphocytes (×10⁹/L)              | Baseline         | 186     | 1.8 (0.7–3.7)      | Week 12 | 180     | 4.2 (1.4–10.3)     | Week 24 | 154     | 4.0 (0.7–9.7)    |
| Neutrophils (×10⁹/L)              | Baseline         | 186     | 4.4 (1.6–12.4)     | Week 12 | 180     | 5.0 (1.6–20.5)     | Week 24 | 154     | 4.9 (1.5–12.7)  |
| Platelets (×10⁹/L)                | Baseline         | 186     | 249 (127–556)      | Week 12 | 169     | 240 (82–3125)      | Week 24 | 155     | 241 (105–590)   |
| Sodium (mmol/L)                   | Baseline         | 186     | 140 (133–148)      | Week 12 | 181     | 140 (134–147)      | Week 24 | 152     | 141 (131–148)   |
| Potassium (mmol/L)                | Baseline         | 186     | 4.3 (3.5–5.1)      | Week 12 | 181     | 4.3 (3.7–5.6)      | Week 24 | 152     | 4.4 (3.5–13.6)  |
| Blood urea nitrogen (mg/dL)       | Baseline         | 176     | 13.7 (4.7–32.0)    | Week 12 | 139     | 14.0 (5.3–24.3)    | Week 24 | 104     | 13.6 (5.0–23.9) |
| Creatinine (µmol/L)               | Baseline         | 186     | 78 (34–143)        | Week 12 | 180     | 77 (33–161)        | Week 24 | 151     | 79 (41–138)       |
| Total bilirubin (µmol/L)          | Baseline         | 186     | 9.6 (2.9–32.1)     | Week 12 | 180     | 8.3 (2.6–35.2)     | Week 24 | 151     | 8.4 (3.2–37.6)  |
| Blood glucose (mmol/L)            | Baseline         | 186     | 5.1 (3.4–17.7)     | Week 12 | 180     | 5.2 (3.0–15.5)     | Week 24 | 152     | 5.2 (3.6–23.8)  |
| Alanine aminotransferase (U/L)    | Baseline         | 185     | 29.0 (6.0–102.0)   | Week 12 | 181     | 26.0 (7.0–241.0)   | Week 24 | 152     | 26.5 (8.0–122.0) |
| Aspartate aminotransferase (U/L)  | Baseline         | 185     | 23.0 (11.0–69.0)   | Week 12 | 181     | 23.0 (10.0–109.0)  | Week 24 | 151     | 23.0 (10.0–123.0) |
| Alkaline phosphatase (U/L)        | Baseline         | 186     | 80.5 (39.0–189.0)  | Week 12 | 181     | 85.0 (32.0–244.0)  | Week 24 | 151     | 86.0 (39.0–298.0) |
| Lactate dehydrogenase (U/L)       | Baseline         | 185     | 187.0 (76.0–398.0) | Week 12 | 181     | 172.0 (152.0–200.0)| Week 24 | 152     | 167.5 (86.0–353.0) |
| Creatine phosphokinase (U/L)      | Baseline         | 186     | 100.5 (17.0–1369.0)| Week 12 | 181     | 92.0 (16.0–470.0)  | Week 24 | 152     | 87.5 (19.0–1528.0) |
| Uric acid (×10⁹/L)                | Baseline         | 186     | 364.0 (149.0–690.0)| Week 12 | 181     | 375.0 (156.0–714.0)| Week 24 | 152     | 356.0 (153.0–684.0) |
meningitis aseptic to be possibly related. During the post-treatment period, pneumonia was reported in the patient who died, which was also considered to be probably related to the trial medication.

Total white blood cell, lymphocyte and neutrophil counts increased during treatment (Table 4). For most patients the maximum toxicity was grade 1. At baseline, none of the 53 patients with evaluable blood samples tested positive for binding antibodies to efalizumab. At Week 32, 9/96 (9.4%) patients tested positive for binding antibodies to efalizumab.

Discussion

In this study, 48.7% of patients reached a PGA rating of at least “excellent” at 24 weeks (ITT LOCF analysis) and 47.6% were classified as PASI-75 responders at this timepoint, consistent with rates reported in European and North American populations [5,6,10]. These findings, however, should be interpreted while considering the main study limitations, which were the open-label design and the lack of placebo arm.

We used an additional measure of “at least good disease control” to determine outcome. As for the “safe psoriasis control” measure proposed by Papp and Henninger [11,12], this endpoint reflects improvements not only in the clinical severity of lesions but also in QoL and an assessment of the tolerability of treatment. By this measure, nearly half of the patients studied derived important benefit from efalizumab treatment without incurring major safety concerns.

The safety profile for efalizumab was also acceptable and consistent with previous results [3–10]; no new safety concerns were identified. AEs occurred most frequently during the first 12 weeks of treatment, the most common events being consistent with the syndrome of influenza-like symptoms or acute AEs that are known to occur with initial efalizumab treatment. Similar to previous trials, the SAEs and AEs most commonly leading to treatment discontinuation were related to exacerbation of psoriasis and/or arthritis [3–10]. Laboratory findings were also consistent with previous experience. Treatment-emergent musculoskeletal and connective tissue disorders were seen in 37.6% of patients, and long-term data have indicated that the incidence of these AEs remains stable for up to 3 years of continuous efalizumab treatment [13].

Although results from the present study indicate that efalizumab has an acceptable safety profile in patients with psoriasis, opportunistic infections have been reported in post-marketing surveillance. In particular, instances of progressive multifocal leukoencephalopathy due to JC virus infection have been observed in patients receiving efalizumab continuously for more than 3 years. After evaluation of all available safety data, the European Medicines Agency has concluded that the benefits of efalizumab therapy no longer outweigh the associated risks and have recommended suspension of marketing authorization (as of 19 February 2009). In addition, efalizumab has been voluntarily withdrawn from the US market.

To our knowledge, the present study is the only prospective trial confirming the efficacy and safety of efalizumab in a Latin American population with moderate-to-severe psoriasis.

Acknowledgements

This study was sponsored by Merck Serono SA—Geneva, an affiliate of Merck KGaA, Darmstadt, Germany. The authors would like to thank fellow members of the Study 25161 group: Argentina—M.A.J. Allevato; Brazil—L.A. Abulafia, T. Cestari, M.D.F. Takahashi, M. de F. Oliveira, J.R. Santamaría, A.M. Roselino; Mexico—L. Dominguez, M.E. Hernández, E. Lopez Cardenas, M.E. De Aillaud, R. Orozco Tópete, V. Santamaría, A. Vera Paramo. They would also like to thank Jenny Fanstone, BSc (supported by Merck Serono SA—Geneva, an affiliate of Merck KGaA, Darmstadt, Germany), for her assistance in preparing the initial draft of the manuscript and collating the comments of the authors.

Conflict of Interest: F.M. Stengel has received honoraria for consultancy, speaker bureau participation and industry-sponsored research from Merck Serono SA; G.L. Dorantes has received honoraria for industry-sponsored research from Merck Serono SA, for advisory board participation from Wyeth and Schering-Plough and for industry-sponsored research from Pierre Fabre; M. López has received honoraria for industry-sponsored research from Merck Serono SA; R.P. Valdez has received grants for industry-sponsored research from Merck Serono SA; M.A. Guerra has received honoraria for industry-sponsored research from Merck Serono SA; E.N. Chouela has received grants and honoraria for consultancy, speaker bureau participation and industry-sponsored research from Merck Serono SA; D. Licu is an employee of Merck Serono SA; V. Petri, G.A.M. Campbell, R.L. Galimberti and L.F. de Arruda have identified no conflict of interest.
Corresponding Author: Fernando M. Stengel, Centro de Educacion Medica e Investigaciones (CEMIC), Clinicas “Norberto Quirno”, Buenos Aires, Argentina; Tel: +54 11 4375 1003; Fax: +54 11 4021 8200; E-mail: fernando@stengeldermato.com.ar

References

1. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: An assessment of the benefits and risks. Br J Dermatol 2005;152:597–615.

2. Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): Mechanisms of action. Dermatology 2004;208:297–306.

3. Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a Phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170–81.

4. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073–80.

5. Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004;3:614–24.

6. Gottlieb AB, Hamilton T, Caro I, Kwon P, Compton PG, Leonardi CL, Efalizumab Study Group. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006;54(4 suppl 1):S154–63.

7. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004–13.

8. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: Results of a three-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008;158:1107–16.

9. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized Phase III trial. J Am Acad Dermatol 2005;52:425–33.

10. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31–8.

11. Papp KA, Henninger E. Evaluation of efalizumab using safe psoriasis control. BMC Dermatol 2006;6:8.

12. Papp KA, Henninger E. Safe psoriasis control: A new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatment. J Cutan Med Surg 2005;9:276–83.

13. Takahashi MD, Chouela EN, Dorantes GL, Roselino AM, Santamaria J, Allevato MA, et al. Efalizumab in the treatment of scalp, palmoplantar and nail psoriasis: Results of a 24-week Latin American study. Arch Drug Info 2009;in press.